A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05701995
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days.
  • Placebo — OTHER
    Specified dose on specified days.

Study Details

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Key Dates

Start date
Jan 31, 2023
Status verified
May 2026
Primary completion
Aug 23, 2024
Completion
May 29, 2025

Study Design

Enrollment
180 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib
  • Placebo Comparator: Placebo then Deucravacitinib

Primary Outcome Measure

Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 [ Time Frame: At Week 16 ]

Locations (35)

FacilityCityStateZIPSite coordinators
Local Institution - 0006PhoenixArizona85006-
Local Institution - 0034ScottsdaleArizona85260-
Local Institution - 0015North Little RockArkansas72117-
Local Institution - 0004BakersfieldCalifornia93309-
Local Institution - 0009SacramentoCalifornia95815-
Local Institution - 0022San DiegoCalifornia92103-
Local Institution - 0030CentennialColorado80111-
Local Institution - 0024Washington D.C.District of Columbia20016-
Local Institution - 0027BrandonFlorida33511-
Local Institution - 0016Coral GablesFlorida33134-
Riverchase DermatologyPembroke PinesFlorida33028-
Local Institution - 0037AtlantaGeorgia30331-
Local Institution - 0020SnellvilleGeorgia30078-
Local Institution - 0007Rolling MeadowsIllinois60008-
Local Institution - 0025SkokieIllinois60077-
Local Institution - 0036SpringfieldIllinois62703-
Local Institution - 0003Baton RougeLouisiana70809-
Local Institution - 0018RockvilleMaryland20850-
Local Institution - 0010Auburn HillsMichigan48326-
Local Institution - 0002WaterfordMichigan48328-
Local Institution - 0017Las VegasNevada89148-
Local Institution - 0035RenoNevada89509-
Local Institution - 0013New YorkNew York10128-
Local Institution - 0032New YorkNew York10011-
Local Institution - 0001RochesterNew York14623-
Local Institution - 0005BexleyOhio43209-
Local Institution - 0012Mayfield HeightsOhio44124-
Local Institution - 0019CharlestonSouth Carolina29407-
Local Institution - 0029CypressTexas77433-
Local Institution - 0028FriscoTexas75034-
Local Institution - 0008South JordanUtah84095-
Local Institution - 0033SpringvilleUtah84663-
Local Institution - 0021BellevueWashington98004-
Local Institution - 0031Mill CreekWashington98012-
Local Institution - 0014SpokaneWashington99202-

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Local Institution - 0006· Phoenix, AZLocal Institution - 0034· Scottsdale, AZLocal Institution - 0015· North Little Rock, ARLocal Institution - 0004· Bakersfield, CALocal Institution - 0009· Sacramento, CALocal Institution - 0022· San Diego, CA

Related Studies